Prednisone treatment

Phase 3Small molecule

CCentre Hospitalier Universitaire Dijon

Prednisone treatment is one of 5 small molecule programs targeting Giant Cell Arteritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell ArteritisActive, not recruiting

Giant Cell ArteritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Giant Cell Arteritis

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Approved

9 2

Orencia

Bristol-Myers Squibb

Phase 3

3 3

Trexall

Jazz Pharmaceuticals

Phase 3

3 4

Tracleer

Johnson & Johnson

Phase 2

1 5

Prednisone treatment

CCentre Hospitalier Universitaire Dijon

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Giant Cell Arteritis

NCT03892785

Clinical

Trials by Indication[1]

Giant Cell Arteritis2 trials

Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis

Completed·—·Phase 2·NCT03711448·38 enrolled

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Active, not recruiting·—·Phase 3·NCT03892785·230 enrolled

Uveitis1 trial

A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)

Terminated·—·Phase 2·NCT03847272·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Prednisone treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prednisone treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prednisone treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire Dijon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCentre Hospitalier Universitaire Dijon

Prednisone treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Giant Cell Arteritis2 trials

Uveitis1 trial

References

Drug Info

Quick Facts

Related News